Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Sygnature Discovery appoints Dr Gerry Thomas as Director of Business Development

Sygnature Discovery Limited, the UK’s largest independent integrated drug discovery provider, today announced the appointment of Dr Gerry Thomas to the pivitol role of Director of Business Development.

Board Director, Dr Paul Clewlow, stated, “I am delighted to welcome Gerry Thomas to Sygnature Discovery. Gerry is a very experienced industry professional having spent over 20 years in drug discovery and development at Boots Pharmaceuticals, BASF/Knoll, OSI Pharmaceuticals, Prosidion and Shire Pharmaceuticals. Sygnature Discovery has ambitious plans to expand its customer base and Gerry will be instrumental in promoting Sygnature’s integrated drug discovery capabilities and expertise across Europe and North America. Gerry is a PhD medicinal chemist with considerable experience and an in-depth knowledge of the drug discovery and development process.”

Dr Gerry Thomas, Director of Business Development, added, “I am pleased to join Sygnature Discovery to work with Paul and his senior scientific colleagues and continue the impressive growth the company has been experiencing over the past 10 years. I know Sygnature well having been a client and was extremely impressed with their capabilities, expertise and determination to deliver on challenging drug discovery projects. So, when the opportunity arose, I was very happy to join the company. I am looking forward to the challenge of promoting Sygnature’s integrated drug discovery services using my know-how and experience in drug discovery and development.”

Latest News

View All

RenaSci’s Sharon Cheetham awarded BPS Fellowship

Sygnature Discovery invests in high-throughput screening capability

Sygnature Discovery moves US base to Kendall…

Sygnature Discovery raises over £2,776 for Cancer…

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.